LP
LYEL icon

LMR Partners’s Lyell Immunopharma LYEL Stock Holding History

LMR Partners’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,250
Closed -$1.38M – 1115
2021
Q2 		$1.38M Buy
+4,250
New +$1.39M 0.02% 459

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

LMR Partners's LYEL Position: Q3 2021 in Review

LMR Partners sold out of Lyell Immunopharma (LYEL) in Q3 2021, closing a stake of 4,250 shares — an estimated $1.38M sold.

LMR Partners first reported a position in LYEL in Q2 2021 and held it in 1 quarter. The position peaked at $1.38M in Q2 2021. 62 funds tracked by Wall St. Rank hold LYEL as of Q3 2021.

  • LMR Partners reported no remaining Lyell Immunopharma position as of Q3 2021 after selling out during the quarter.
  • LMR Partners sold 4,250 Lyell Immunopharma shares in Q3 2021, an estimated $1.38M.
  • LMR Partners first reported a position in Lyell Immunopharma in Q2 2021 and held it in 1 quarter.
  • LMR Partners's Lyell Immunopharma position peaked at $1.38M in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.